Microchips Biotech Technology 6 TH ANNUAL PHARMACEUTICAL PROGRAM

Microchips Biotech Technology 6 TH ANNUAL PHARMACEUTICAL PROGRAM SYMPOSIUM INNOVATIVE ACCESS: USING TECHNOLOGY TO IMPROVE DELIVERY, QUALITY, AND USE OF MEDICINES March 22, 2017 CONFIDENTIAL • © MICROCHIPS BIOTECH

The Microchips Biotech Opportunity Drug Delivery The world’s most advanced electronic implantable drug delivery system with over 15 years of research, engineering and clinical data behind it Drug Adherence Tackling the $290 billion problem of drug adherence by integrating revolutionary digitally-controlled drug delivery into the healthcare system 2 CONFIDENTIAL • © MICROCHIPS BIOTECH Validating partnerships in several important therapeutic areas – TEVA and Bill & Melinda Gates Foundation System Modularity Commercially viable platform across multiple applications leveraging our modular system Investors Founders Robert Langer, Sc. D Strong Partnerships Michael Cima, Ph. D

Overview of Device Platform • Microchip-based Implant – Self-contained, battery-powered drug delivery device capable of wireless communication – Stores hundreds of therapeutic drug doses for release over months or years – Implanted subcutaneously in physician’s office (abdomen or other anatomical locations) 200 Reservoirs; ~ 22 x 28 x 8 mm 3 CONFIDENTIAL • © MICROCHIPS BIOTECH 400 Reservoirs ~ 22 x 40 x 8 mm

Overview: How the Technology Works Drug Storage • Individual doses are stored in micro-reservoir arrays • Reservoirs are hermetically sealed at room temperature • Thin metallic membranes over each reservoir protect drug post-sealing Drug Release • Drug doses are initiated automatically on schedule or wirelessly on-demand by patient or clinician • Reservoirs are opened via electrothermal activation of membranes • Upon opening, interstitial fluid diffuses in and drug diffuses out 4 CONFIDENTIAL • © MICROCHIPS BIOTECH

Numerous Real-time Solutions for Drug Adherence • Improving convenience for established therapies that require frequent, long-term dosing, or delivery via injection including freedom from injection pain and infection risk • Improving drug effectiveness and outcomes where compliance is critical in both chronic and acute diseases • Automatic dosing for patients with compliance difficulties including the elderly, psychiatric patients and patients with cognitive dysfunction • Developing countries where patients cannot access regular healthcare Compliance = Improved Outcomes = Improved Healthcare 5 CONFIDENTIAL • © MICROCHIPS BIOTECH

Broad Therapeutic Applicability Orphan Indications The Microchips platform has broad applicability across therapeutic indications including osteoporosis, diabetes and other chronic diseases and women’s contraception. Women’s Health Autoimmune Disorders Microchips Platform Cognitive Disorders CVD Chronic Diseases 6 CONFIDENTIAL • © MICROCHIPS BIOTECH